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Background: In recent years, China has experienced tremendous growth in its pharmaceutical industry. Both the
Chinese government and private investors are motivated to invest into pharmaceutical research and development
(R&D). However, studies regarding the different behaviors of public and private investment in pharmaceutical R&D
are scarce. Therefore, this paper aims to investigate the current situation of public funding and private investment
into Chinese pharmaceutical R&D.
Methods: The primary data used in the research were obtained from the China High-tech Industry Statistics
Yearbook (2002–2012) and China Statistical Yearbook of Science and Technology (2002–2012). We analyzed public
funding and private investment in five aspects: total investment in the industry, funding sources of the whole
industry, differences between provinces, difference in subsectors, and private equity/venture capital investment.
Results: The vast majority of R&D investment was from private sources. There is a significantly positive correlation
between public funding and private investment in different provinces of China. However, public funding was likely
to be invested into less developed provinces with abundant natural herbal resources. Compared with the chemical
medicine subsector, traditional Chinese medicine and biopharmaceutical subsectors obtained more public funding.
Further, the effect of the government was focused on private equity and venture capital investment although
private fund is the mainstream of this type of investment.
Conclusions: Public funding and private investment play different but complementary roles in pharmaceutical R&D
in China. While being less than private investment, public funding shows its significance in R&D investment. With
rapid growth of the industry, the pharmaceutical R&D investment in China is expected to increase steadily from
both public and private sources.
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In recent years, China has experienced a rapid growth in
its pharmaceutical industry. In 2012, the pharmaceutical
market in China increased by 12% to reach about 154
billion USD, and is expected to reach $383 billion by
2020 [1], making China one of the largest pharmaceutical
markets globally. Meanwhile, a shift to more advanced
pharmaceutical research and development (R&D) has
started out in China recently. The Chinese government
is dedicated to making more considerable investments
in new drug R&D. Typically, in the 12th Five-Year Plan,* Correspondence: haohu@umac.mo; ytwang@umac.mo
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reproduction in any medium, provided the orthe Key Drug Innovation Program initiated by the govern-
ment will receive 10,000 million Chinese Yuan (CNY)
(about 1,653 million USD according to the exchange rate
of 6.05 at the end of 2013) from the central government
and 30,000 million CNY (about 4,959 million USD) from
local governments [2]. Private investors are also motivated
to invest huge funding into pharmaceutical R&D. As a
result, R&D investment in the Chinese pharmaceutical
industry has sharply increased [3].
However, studies regarding the different behaviors of
public and private investment in pharmaceutical R&D
are scarce. Since China is such a large emerging country,
funding source distribution in different provinces might
vary widely, as well as in different subsectors. Further, as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the current status of private equity (PE) and venture
capital (VC) in Chinese pharmaceutical R&D investment
also remains unclear.
Therefore, this paper aims to investigate the current
situation of public funding and private investment in the
Chinese pharmaceutical R&D. In particular, an exploration
of public funding and private investment in different prov-
inces and subsectors can help us to observe the diverse
preferences of public and private investment in pharma-
ceutical R&D, to better understand government guidance
for the Chinese pharmaceutical industry, and to identify
investment opportunities and patterns in different regions
and subsectors.
Theoretical review
Recently, the Chinese government has published a series
of policies to promote new drug innovation, outlining
several objectives which can be considered as a systematic
development strategy of China’s new drug innovation: to
provide support to establish advanced-level platforms for
drug discovery and development; to discover new molecu-
lar entities, new biologics (first-in-class and best-in-class)
and new drugs with independent intellectual property (IP)
rights; to improve modern Chinese medicine system; and
to develop prospective technologies for drug R&D [2].
While such types of plan demand a joint effort of public
funding and private investment, how to appropriately
position two types of funding sources still requires further
theoretical exploration.
Theoretically, in order to guarantee the public use of
knowledge, which is the basis of applied development
research, public funding is considered to be effective for
basic research to generate knowledge into the form of
public products [4-7]. However, knowledge from applied
research and development is exclusive to some extent.
Enforcement of an IP system could bring exclusiveness.
For instance, patent laws could prevent the public usage
of new knowledge. Private funds can then be injected in
these fields [6].
Previous research on the relationship between govern-
ment R&D funding and private R&D investment has
not yet reached consensus. At the micro level, Link [8]
found that public investment would decrease basic re-
search of enterprises, but promote applied and develop-
ment research. Hamberg [9] thought that subsidies
from the United States’ Department of Defense would
increase R&D investment of enterprises. At the macro
level, Guellec and Van Pottlesberghe [10] have system-
atically studied the effect of public investment on R&D
action of enterprises in 17 OECD countries from 1981
to 1996. They drew an inverted U-shaped line to de-
scribe the relationship between financial support and
tax preferences from the government and the increaseof private R&D investment. Toole [11] found strong evi-
dence that public basic and clinical research were com-
plementary to pharmaceutical R&D investment and
thereby stimulated private industry investment by using
a panel of medical classes observed over 18 years.
In China, Xu and Liu [12] believed the positive effect of
public R&D investment, but Liu and Du [13] found that
ex ante subsidy of the government would not improve the
effort of enterprises’ innovation. Sun and Sun [14] found
that government investment in research institutions did
not significantly affect the R&D expenditures of pharma-
ceutical companies. Gu and Shen [15] found that govern-
ance environment has a positive effect on corporate R&D
activities. Companies tend to carry out more R&D activ-
ities if government interference and the space of rent-
seeking are reduced. Zhao [16] carried out an empirical
study of Guangdong Province on the relationship be-
tween R&D investment and innovation performance,
concluding that the government’s R&D investment had
relevance to the level of innovation.
It is worth mentioning that David [7] collected 32 papers
in this field from 1957; 20 of the papers confirmed the
positive relation between public and private investment, 8
agreed that there was a complement effect between them,
and 4 did not find a significant relationship. In summary,
the literature has not reached a clear conclusion on the
relationship between public funding and private invest-
ment for R&D in the pharmaceutical industry, especially
under the changing situation that China is currently
experiencing.Methods
Data sources
Data was collected from multiple sources in this study.
The primary data used was obtained from the China
High-tech Industry Statistics Yearbook (from 2002 to
2012) and China Statistical Yearbook of Science and
Technology (from 2002 to 2012), both of which were
provided by the National Bureau of Statistics of China.
The statistical data in these two sources covered all
state-owned and non-state-owned enterprises with an-
nual sales revenue above 5 million CNY (about 0.769
million USD). As these enterprises represented the main
industrial components, it is credible to reflect the main
condition and progress of R&D investment in China’s
pharmaceutical industry.
Data of PE and VC in China was collected from a series
of reports from ChinaVenture and Zero2IPO, both of
which are integrated service providers specializing in
providing professional information, data, and consulting
services for PE and VC in China. In addition, compara-
tive data of high-tech industry in other countries was
obtained from the OECD, STAN Database 2011.
Figure 1 Recent changes in the Chinese pharmaceutical industry.
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According to McGuire’s definition in 2007, the pharma-
ceutical industry develops, produces, and markets drugs or
pharmaceuticals which are licensed for use as medications
[17]. Here, we adopted the formal definition of Statistics
Catalogue of High-technology Industry Classifications
from National Bureau of Statistics of China, in which
pharmaceutical industry only means manufacturing of
medicine (code 27); the manufacturing of medical equip-
ment and instrument (code 368) is not included into
pharmaceutical industry [18].
For R&D investment, it was defined as actual internal
expenses on R&D, including direct expenditure on R&D
projects and indirect expenditure on management, service,
basic construction, and cooperation accessing. Since
R&D intensity is the most frequently used measurement
“to gauge the relative importance of R&D across indus-
tries and among firms in the same industry” [19], we
used R&D intensity as the ratio of the industry’s gross
expenditure on R&D compared to the gross industrial
output value.Table 1 Emerging R&D activities in the Chinese pharmaceutic
2000 2005
Personnel for scientific and technologic (S&T)
activities
37,833 51,832
Patent applications 547 2,708




Source: China High-tech Industry Statistics Yearbook.For funding sources, we define funds from government
department at all levels as public funding, and other
funding sources as private investment.
Data analysis
In order to clarify the complicated relationships between
public funding and private investment in China’s pharma-
ceutical industry, we analyzed the data in five aspects: total
investment in the industry, funding sources of the whole
industry, difference in provinces, difference in subsectors,
and PE/VC investment.
First, total investment in the industry was described
by total R&D expenditure and R&D intensity. To get a
better understanding of R&D investment level in China’s
pharmaceutical industry, we also compared R&D intensity
of several high technology industries in China with those
in other selected countries.
Second, funding sources of the whole industry directly
compared the two different sources of funding for R&D
in the industry: public funding and private investment.
Third, differences between provinces were assessed by
comparing public R&D investment intensity and private
R&D investment intensity in different provinces of China.
Here, the Spearman correlation test was applied to test
the correlation between public R&D intensity and private
R&D intensity.
Fourth, for difference in subsectors, China’s pharmaceut-
ical industry was divided into three subsectors: chemical
medicine, traditional Chinese medicine (TCM), and bio-
pharmaceutical medicine. Potential funding differences in
these three subsectors were analyzed by comparison.
Finally, PE/VC investment was analyzed as a special sup-
plement. We collected data of PE/VC investment amount
and number of cases in recent years and listed the typical
cases to highlight those high-tech driven investments.
All statistical calculations were performed with the SPSS
software version 18, and Excel 2003. Figures in CNY were
transformed to USD value by using exchange rates in
2013 unless otherwise specified.
Results
Total investment in the industry
As China’s overall economy has grown rapidly over the
past years, its pharmaceutical industry has also experi-
enced a surge. The gross output value of the Chineseal industry
2007 2008 2009 2010 2011
73,408 90,820 90,222 70,781 118,558












Figure 2 R&D activity of the Chinese pharmaceutical industry
in recent years.
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2000 to 229.88 billion USD in 2011. The revenue and
profit of the industry has also expanded by nearly 10
times during this period, although the number of enter-
prises decreased dramatically in 2011 from over 7,000
to 5,926 (Figure 1).
As the Chinese pharmaceutical industry begins to tar-
get higher-end drug products, domestic investment into
the pharmaceutical innovation has largely increased. The
personnel involved in Scientific and Technologic (S&T)
activities increased to nearly 119,000 in 2011, whereas the
volume of patent applications went up by 19.32 times







China (2011) 1.63 7.82 1.41 0.75
USA (2007) 16.89 9.90 26.57 10.69
Japan (2008) 10.50 2.90 16.40 7.61
Germany
(2007)
6.87 8.65 8.27 4.46
UK (2006) 11.10 10.70 24.92 0.38
France
(2006)
7.74 5.20 8.69 7.94
Italy (2007) 3.82 13.43 1.79 1.23
Canada
(2006)
11.50 6.27 11.88 10.92
Spain (2007) 5.22 6.87 6.25 3.80
Korea (2006) 5.86 9.02 2.51 3.93
Sweden
(2007)
13.18 12.91 13.44 13.92
Denmark
(2006)
– – 18.40 5.09
Norway
(2007)
5.67 1.09 5.48 0.85
Finland
(2007)
11.50 4.81 24.50 2.34
Source: China High-tech Industry Statistics Yearbook.personnel for S&T and patent application numbers in
2010, which may be partially explained by a stricter
regulation resulting from China’s new health care re-
form effective in that year.
The R&D expenditure in China’s pharmaceutical indus-
try has increased from 162.6 million USD in 2000 to
3,249.2 million USD in 2011. The R&D intensity also fluc-
tuated in 2010 and rose back to 1.41% in 2011 (Table 1
and Figure 2). However, it is far less than that of some
other high-tech industries in China, such as the aircraft
and spacecraft industry, with a ratio of 7.82%.
Furthermore, the R&D intensity of the pharmaceutical
industry in the United States and UK in 2007 was
26.57% and 24.92% respectively, which shows a tremen-
dous gap between China and other developed economies
in pharmaceutical R&D investment (Table 2).Funding sources of the whole industry
The majority of R&D investment was from self-raised
funds of pharmaceutical enterprises in this R&D booming
period. The percentage of private investment in the overall
R&D investment was 71.5% in 1995 and increased to
92.73% in 2011. Meanwhile, the percentage of government
funds rose slightly from 2.5% in 1995 to 6.03% in 2011.
Other sources decreased obviously from more than 20%





















Figure 3 Change of R&D sources in the Chinese pharmaceutical
industry.
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The map of provincial R&D intensity in 2011 presented
a regional imbalance of R&D investment (Figure 4). The
R&D intensity of the eastern region of China was 1.88%,
which is higher than the average ratio of 1.41%, and it
was 0.839% and 0.778%, respectively, for the middle and
western regions of China.
There were 17 provinces or municipality cities with an
above average ratio, from which two municipality cities –Figure 4 Provincial imbalance of R&D intensity in pharmaceutical indTianjin with 2.987% and Shanghai with 2.963% – were the
two highest. It is a little surprising that Fujian, Zhejiang,
and Gansu followed closely, as opposed to those provinces
known to have a large-scale pharmaceutical industry such
as Shandong or Jiangsu (see navy blue areas in Figure 4).
Shandong was the sixth and Jiangsu ranked outside the
top 10 provinces.
However, according to the ratio of investment from
government to output value (Table 3), the ranking was a
little different. Gansu jumped to the first, nearly twice of
the second, Tianjin. Gansu is a typical province where
pharmaceutical industry development is mainly promoted
by the local government based on its rich Chinese
herbal resources, although it is one of the least devel-
oped provinces in China. The export volume of its
Chinese angelica, Codonopsis pilosula, and Astragalus
mongholicus accounted for more than 80% of China’s
total amount. Recently, the high volume of funding has
been invested in the modernization of TCM R&D in
Gansu.
Guangdong, Hainan, and Chongqing ranked behind
Tianjin. Guangdong, ranking as the fourth in gross
pharmaceutical industrial output value in China, injected
both public and private resources into the industry.ustry.













Source: China High-tech Industry Statistics Yearbook; China Statistical
Yearbook.
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decreased to the eleventh. Zhejiang, which is famous for
its small enterprises and free-market environment, was
listed as fourteenth.
The Spearman correlation test showed that the correl-
ation coefficient between private R&D intensity and gov-
ernment R&D intensity was 0.689 (Table 4). The scatter
figure also showed their positive correlation; however,
Gansu was slightly distinctive because of its high govern-
ment R&D investment intensity compared with its pri-
vate R&D investment intensity (Figure 5).Difference in subsectors
In 2011, 57.99% of R&D investment, totaling 1.9 billion
USD, was put into the chemical medicine subsector, the
TCM subsector received 18.32% or 0.6 billion USD, and
the biopharmaceutical subsector attracted 0.45 billion
USD, accounting to 13.89%. The percentage of R&D in-
vestment in chemical medicines had kept above 60%
during most years from 2000 to 2013, but the ratio of
TCM decreased from 24.5% in 2000 and the biopharma-
ceutical subsector attracted more and more funds during
this period (Figure 6).
In 2011, public investment in chemical medicines
reached 105.7 million USD, being much higher than theTable 4 Spearman correlation test for public and private R&D
Rho of Spearman Private R&D intensity Correlation coeff
Sig. (2 tailed)
N
Government R&D intensity Correlation coeff
Sig. (2 tailed)
N
**P <0.01.sum of that in TCM (41.87 million USD) and biophar-
maceuticals (26.65 million USD) (Figure 7).
Table 5 shows the scale of public investment in three
subsectors. The fact that most governmental resources
had been invested into the chemical medicine subsector
has not changed in the past decade, and may be related
to the large scale and number of chemical medicine firms
in China. However, the biopharmaceutical subsector expe-
rienced the fastest growth; the public investment in the
biopharmaceutical subsector increased by more than 13
times from 2000 to 2011, while the remaining two subsec-
tors increased by 9.5 and 8.4 times, respectively.
More details about percentage of public R&D invest-
ment in total R&D investment showed that the percent-
age of public investment in the chemical medicine
subsector had kept on around 5%, and the percentage of
public investment in the biopharmaceutical subsector
was the highest but not stable. The percentage of public
R&D investment in all three subsectors increased before
2009 and decreased in 2011 (Figure 8).
PE/VC investment
Similar with most countries, private investment was the
main source of China’s PE/VC. In 2012, unlisted com-
panies accounted for 34.03% of the total VC sources and
individual sources accounted for 18.87% [20]. The gov-
ernment and state-owned enterprises together accounted
for 30.59% (Figure 9).
It is worth mentioning that there is a VC Guiding
Fund (VCGF) which had made a cumulative investment
of 28.9 billion CNY (4.44 billion USD) by the end of
2012. These investments operated by governments have
been injected into VC by buying VCs shares, risk subsid-
ies, and investment guarantee. In 2012, 5% of investment
of VCGF-backed VC has been input in pharmaceutical
and healthcare industry.
According to Zero2IPO Research Center, in 2012,
China’s PE market completed 680 investment deals, of
which 606 deals disclosed 19.79 billion USD in total.
Among these deals, biopharmaceutical investment held
the majority. Figure 10 presents the increase of PE/VC
investment deals and amounts in China in the past sev-
eral years. There was a decline in 2008 and 2009 whenintensity







Figure 5 Scatter diagram of public and private R&D intensity in different provinces.
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financial crisis, but the situation improved and the PE/
VC investment hit a new high in 2011.
PE investment cases in 2012 are listed in Table 6, show-
ing that companies focusing on a particular high-tech field
or a particular market segment, though in a small scale,
were preferred by institutional investors. For example,
Luye Pharma Group Ltd. is well known by its successful
TCM innovation and long-acting sustained-release micro-
sphere preparation R&D, while Gansu Longshen Rongfa
Pharmaceutical Co., Ltd. engages mainly in the cutting-
edge research of TCM.
Discussion
Overall, we have observed a rapid increase of investment
in Chinese pharmaceutical R&D during the past decade,Figure 6 Percentage change of R&D investment in three
subsectors.although the investment intensity is still behind other
high-tech industries around the world. The results indi-
cate that China still needs more pharmaceutical R&D in-
vestment to realize its objective of developing a competent
pharmaceutical innovation system.
Private investment as a main funding source
As our data showed, private investment was the main
funding source for pharmaceutical R&D in China. It is
understandable for private investors to choose to invest
in applied research and development research; however,
if the increasing public input cannot fully support basic
research and early stage R&D activities, the Chinese
pharmaceutical industry will not be able to reach high
levels until after many years’ effort. Further, drug R&DFigure 7 Proportion of public R&D investment in three
subsectors in 2011.
Table 5 Scale of public R&D investment in three subsectors (10,000 CNY)
2000 2005 2006 2007 2008 2009 2010 2011
















































Source: China High-tech Industry Statistics Yearbook.
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drugs, are time-consuming [21,22]. This may hinder
private investors, who are seeking short-term return,
from injecting their money in early drug R&D stages.
Meanwhile, in China, what puzzles institution investors
mostly is how to withdraw capital gains because of strict
initial public offering regulations and an underdevel-
oped merger/acquisition market.
For private investors, the best solution is to increase
the firm’s profit expectation of R&D. Firms with a sig-
nificant IP stake in China could put in place an effective
protection and enforcement strategy against local and
overseas competitors [23]. Practical and effective IP
protection and enforcement strategies should be an in-
tegrated part of a firm’s overall strategy. Mortgage on IP
has also been undertaken in some cities in China and
could have great potentials, although problems, such
as valuation and liquidation of IP, have not yet been
resolved.
Differences of public and private R&D investment in
provinces
Many studies have concluded that pharmaceutical firms
prefer to cluster around developed areas with sufficient
talents and massive funds [24-26]. However, in many
countries, industry agglomeration is usually led by both
the government and market; the same is true in China.
Gansu Province ranked the first in the public R&D in-
vestment intensity list, mainly because of its large volumeFigure 8 Percentage change of public funding in three
subsectors.of herbal resources. However, due to its remote location
from the eastern and southern economy centers of China,
the scale of its whole economy and pharmaceutical indus-
try is very limited. The gross industrial output value of
Gansu Province in 2012 was 958 million USD, ranking
fourth last among all provinces. It is obvious that the main
objective of public funding should be to support industrial
development in less developed areas.
It is not surprising that Tianjin ranked almost the
highest in both the lists of public R&D investment inten-
sity and total R&D investment intensity. Since Binhai
New Area in Tianjin was established as a new administra-
tive division in 2009, the local government strongly pro-
moted scientific, technological, and financial innovations
and took great efforts to establish science and technology-
based financial conglomerates [27]. As a result, investment
on high-tech industry, including the biopharmaceutical in-
dustry, has been high in that region. It ranked as the best
investment area in China in 2010.
Shanghai, with its Zhangjiang Hi-Tech Park being
already the largest new drug R&D base in China, has
attracted relatively more investment from enterprises,
including many multinational pharmaceutical companies
like Novartis, GlaxoSmithKline, and Pfizer. More than
210 pharmaceutical companies and dozens of drug R&D
institutes or centers have been established in Shanghai.
In general, the provinces with high R&D investment
intensity are mainly distributed in eastern and southern
China. Both the scatter chart and Spearman test show
us an obvious positive relationship between public
funding and private investment. The possible situation
is a mutual promotion: local governments in provincesFigure 9 Capital sources of Chinas venture capital.
Figure 10 Booming PE/VC in Chinese pharmaceutical industry.
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capital in R&D and have ability to do so, on the con-
trary, private investments are guided and attracted by
favored government funding policies.
Besides the developed districts like Tianjin, Shanghai,
and Guangdong Province, half of the top 10 provinces
with the highest public investment intensity are develop-
ing areas with abundant natural resources, such as Gansu,
Yunnan, Hainan, and Guizhou Provinces. Governments
in these provinces lean towards developing the TCM in-
dustry by favored policies and public funding, which
also promote the investment from private investors.
Differences of public and private R&D investment in
subsectors
The chemical medicines subsector is the largest in China’s
pharmaceutical industry, and China is the largest exporter
of active pharmaceutical ingredients [28]. Accordingly,
we have observed a constant and large volume of R&D
investment into this subsector, being the subsector with
the largest public investment. However, if the percent-
age of public investment in the three subsectors is taken
into account, the highest percentage of investment was
observed in the biopharmaceutical subsector before
2007, and TCM became the highest between 2007 and
2009. After 2009, the biopharmaceutical was once again
the highest.
The percentage change of public R&D investment in the
three subsectors partially reflects government intentions.Table 6 PE investment cases in 2012
Enterprises Amount
Nantong Novast Pharmaceuticals Co., Ltd. 20 million USD
Gansu Longshen Rongfa Pharmaceutical Co., Ltd. 2.9 million USD
Luye Pharma Group Ltd N/A
Shaanxi Bicon Pharmaceutical Co., Ltd. 250 million USD
Kaifeng Pharmaceutical (Group) Co., Ltd. 14.7 million USD
Source: ChinaVenture.A large problem in the current pharmaceutical industry
in China is the over-capacity of active pharmaceutical
ingredients and chemical drugs without high technical
innovation [29]. Therefore, the overall profits of the
pharmaceutical industry have been decreasing; a new
driving force is required to push the industry.
The shift from pharmaceutical development towards
discovery research may originate from two considerations.
The first is to deepen the R&D of TCM, which has not
been widely accepted in western countries. In recent years,
the percentage of public R&D investment in the TCM
subsector reached 8%. Meanwhile, a list of development
strategies of TCM has been released by the Chinese
government. Another signal is that the new Essential
Drug List was promulgated in early 2013, including 203
TCMs among 520 drugs in total. There are 40 exclusive
TCM products, and each of them is authorized to be pro-
duced by only one TCM firm [30]. It is a policy sign to
attract more attention and investment on modernization
of TCM.
The second is to seize the growth opportunity of bio-
pharmaceutical S&T. Successive and increasing invest-
ments, an especially high percentage of public R&D
investments, reflect the potential growth of the bio-
pharmaceutical subsector in China. Many policy makers
in China believe that the biopharmaceutical field is one
in which Chinese pharmaceutical firms can become
world leaders. Despite the impassable gulf between
Chinese firms and enterprises in developed countries in
the field of chemical medicines, the short history of
China in the biopharmaceutical field opens the possibil-
ities of it becoming world leader. Both governmental
and private sources have been attracted to this field;
high-tech companies, which take advantage of genetic
engineering technologies to develop genomic drugs, are
favored by Chinese private investors.
PE and VC in China’s pharmaceutical industry
In 1998, a proposal to Develop Venture Capital Invest-
ment in China by the National Committee of the Chinese
People’s Political Consultative Conference was considered
to be a trigger to attract VC investment for high-tech
industries. Particularly, in the stock exchange market,Investor Issue time
Lilly Asia Ventures 13/6/2012
Genertec Investment Managers Ltd. 29/3/2012
CDH Investments; CITIC Private Equity Funds
Management Co., Ltd.; New Horizon
3/2/2012
Pacific Alliance Group 28/2/2012
N/A 20/2/2012
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in 2004 and the Growth Enterprises Market Board in
2009, stimulated the acceleration of PE and VC. Besides,
a series of government policies, as well as Company
Law and Securities Law, have been promulgated to pro-
mote investor entry, market access, and capital exit for
PE and VC.
Currently, in China, both case number and amount of
PE and VC investment are in a rising channel. As data
shows, the proportion of individuals and foreign capital
increased significantly, mainly because the Chinese gov-
ernment encourages foreign capital to invest in high-tech
industries. It also led to significant increases of individual
investors as angel investors.
Although the vast majority of investment amount of
VC is from private sources, government inflcuence is
still of significance. For example, the most important in-
formation channel of VC investment projects is govern-
ment recommendation, which has kept on more than
25% among all information channels in the past 5 years.
According to a survey in 2012, 18.9% of VC investors
thought the main reason for unsuccessful investment
was policy change in the policy environment [31]. Spe-
cific to investment behavior, VCGF-backed VC is more
likely to invest in medicine and healthcare industry, and
to select projects in a mature stage [31].
The greatest difficulty for PE and VC in China is the
lack of an efficient investment exit channel. As a result,
many PE and VC focus on short-term and less innovative
projects. More investment exit channels will effectively
promote PE and VC investors to seek more long-term
and creative projects, which will certainly benefit the
innovation of pharmaceutical R&D in China.
Conclusions
Public funding and private investment play different
but complementary roles in the pharmaceutical R&D of
China. Public funding tends to be injected into some
undeveloped provinces, and biopharmaceutical and TCM
subsectors. While being less than private investment, pub-
lic funding shows its significance in R&D investment.
With rapid industry growth, the pharmaceutical R&D in-
vestment in China is expected to keep a constant increase
from both public and private sources.
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